Another inhibitor, 4-iodo-6-phenylpyrimidine (4-IPP), reduced tumor cell proliferation and motility (238), improved survival in melanoma-bearing mice (193) and enhanced the effectiveness of anti-CTLA-4 therapy by increasing CD8+ T-cell infiltration and metabolic reprogramming (194). The gene discussed is CD8A; the disease is neoplasm.